Para IV notice: Endo International gets Paragraph IV notification on Vasostrict
Posted on19 Apr 2018
Comments0
Endo International plc announced that its subsidiaries, Par Pharmaceutical, Inc. and Par Sterile Products, LLC, have received a Notice Letter dated April... Read More
Licensing Case Study: Nuvo Ireland’s acquisition of US rights for Resultz from Piedmont Pharma
Posted on17 Jan 2018
Comments0
Nuvo Pharmaceuticals Inc. (Nuvo), a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, announced that its wholly... Read More
What is the well-known mark? How it differs from regular trademark?
A famous or well-known mark is a trademark that, in view of its widespread reputation or recognition, may enjoy broader protection than... Read More
“Assignment of a TradeMark” – What is that mean?
This is a legal term associated with trademark. When one trademark owner transfer it’s trademark to another party, the term trademark assignment... Read More
Licensing Deal Analysis: Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics
Immunomic exclusively licensed patent portfolio from Annias Immunotherapeutics for use in combination with Immunomic’s investigational LAMP-Vax technology Underlying technology is currently in... Read More
NCK Pharma to introduce new edged “EMOTION BASED LEARNING” in the field of Pharmaceutical Learning
Bangalore (India), Press Release — NCK Pharma Solution Private Limited (popularly know as NCK), leading diversified training provider in the filed of... Read More
Battle of Pharmaceutical Trademark: GlaxoSmithKline wins ‘GSK’ trademark battle in India
GlaxoSmithKline wins in a three-years long court battle over its trademark rights with a Hyderabad company which used the same acronym. What... Read More
Case Study: Curious Case of Remicade bio-pharma patent battle with Inflectra
Posted on22 Aug 2016
Tagsbiopharma patent battle, biopharmaceuticals, Celltrion, Hospira, Inflectra, Johnson & Johnson, pfizer, Remicade, Remicade biosimilar
Comments0
Biopharmaceutical: Infliximab Class: monoclonal antibody Brand Name: Remicade Marketed By: Johnson & Johnson ——————————– Biosimilar of Infliximab is Inflectra. ——————————– Infliximab (trade... Read More
Boehringer Ingelheim, University of Dundee collaboration for newer class of drug development – proteolysis-targeting chimeras (PROTACs)
Boehringer Ingelheim and the University of Dundee will join forces in an exciting collaboration with the aim to develop a novel class... Read More
Gilead gets Indian patent for Hepatitis C drug Solvadi
Brand Name: Sovaldi Molecule: Sofosbuvir Innovator Company: Gilead Sciences In direct contradiction to its earlier order, the Controller General of Patents, Designs... Read More